Medullary pain facilitating neurons mediate allodynia in Headache-Related pain

Annals of Neurology

Volumn 65, Issue 2, 2009, Pages 184-193

  Edelmayer, Rebecca M ^a   Vanderah, Todd W ^a   Majuta, Lisa ^a   En Tan, Zhang ^a   Fioravanti, Beatriz ^a   De Felice, Milena ^a   Chichorro, Juliana G ^a   Ossipov, Michael H ^a   King, Tamara ^a   Lai, Josephine ^a   Kori, Shashi H ^b   Nelsen, Andrew C ^b   Cannon, Keri E ^c   Heinricher, May M ^c   Porreca, Frank ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPIVACAINE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CHOLECYSTOKININ RECEPTOR; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; NAPROXEN; NEUROKININ 1 RECEPTOR ANTAGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG; YMO 22;

ALLODYNIA; ANIMAL EXPERIMENT; ARTICLE; BRAIN STEM; CANNULA; CLINICAL OBSERVATION; CONTROLLED STUDY; DURA MATER; ELECTROPHYSIOLOGY; FACE PAIN; FACILITATION; HEADACHE; INFLAMMATION; MALE; MIGRAINE; NERVE CELL; NONHUMAN; PAIN; PERCEPTIVE THRESHOLD; PHYSIOLOGY; PRIMARY HEADACHE; PRIORITY JOURNAL; RAT;

ACTION POTENTIALS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRADYKININ; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DURA MATER; HEADACHE DISORDERS; HYPERALGESIA; INFLAMMATION; MALE; MEDULLA OBLONGATA; NEURONS; NEUROTRANSMITTER AGENTS; ONCOGENE PROTEINS V-FOS; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; TRIPELENNAMINE;

EID: 62549085177     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21537     Document Type: Article

References (39)

1. Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache 2006;46(suppl 4): 182-191.
2. Diener HC, May A. New aspects of migraine pathophysiology: lessons learned from positron emission tomography. Curr Opin Neurol 1996;9:199-201.
3. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47:614-624.
4. Burstein R, Yamamura H, Malick A, et al. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neuro-physiol 1998;79:964-982
5. Malick A, Jakubowski M, Elmquist JK, et al. A neurohisto-chemical blueprint for pain-induced loss of appetite. Proc Natl Acad Sci U S A 2001;98:9930-9935.
6. Oshinsky ML, Gomonchareonsiri S. Episodic dural stimulation in awake rats: a model for recurrent headache. Headache 2007; 47:1026-1036.
7. Ossipov MH, Porreca F. Mechanisms of pain facilitation systems: implications for medication overuse headache. In: Jensen TS, Olesen J, eds. From basic pain mechanisms to headache. Vol 14. Oxford: Oxford University Press, 2006:185-193.
8. Heinricher MM, Ingram SL. The brainstem and nociceptive modulation. In: Bushnell MC, Basbaum AI, eds. The senses, a comprehensive reference. Vol 5. Pain. San Diego: Academic Press, 2008:593-626.
9. Porreca F, Burgess SE, Gardell LR, et al. Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor. J Neurosci 2001;21: 5281-5288.
10. Xie JY, Herman DS, Stiller CO, et al. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci 2005;25: 409-416.
11. Jakubowski M, Levy D, Goor-Aryeh I, et al. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005:45:850.....861.
12. Landy SH, McGinnis JE, McDonald SA. Clarification of developing and established clinical allodynia and pain-free outcomes. Headache 2007;47:247-252.
13. Doods H, Arndt K, Rudolf K, et al. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci 2007;28:580-587.
14. Ho TW, Maunix LK, Fan X, et al. Randomized controlled trial of an oral CGRP antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70:1304-1312.
15. King T, Ossipov MH, Vanderah TW, et al. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals 2005;14: 194-205.
16. Goldstein DJ, Wang O, Saper JR, et al. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997;17:785-790.
17. Goldstein DJ, Offen WW, Klein EG, et al. binepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 2001;21: 102-1 06.
18. Sjaastad O, Bakketeig LS. The rare, unilateral headaches. Vaga study of headache epidemiology. J Headache Pain 2007;8: 19-27.
19. Pareja JA, Sjaastad O. SUNCT syndrome. A clinical review. Headache 1997;37:195-202.
20. Hunt SP, Pini A, Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 1987:328:632-634.
21. Bereiter DA, Hargreaves KM, Hu JW. Trigeminal mechanisms of nociception: peripheral and brainstem organization. In: Bushnell MC, Basbaum AI, eds. The senses, a comprehensive reference. Vol 5. Pain. San Diego: Academic Press, 2008: 435-460.
22. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004;55:19-26.
23. Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia 2007;27:1055-1060.
24. Goadsby PJ, Zanchin G, Geraud G, er al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008;28:383-391.
25. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004;55:27-36.
26. Lew D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/ID receptor agonists. Proc Natl Acad Sci (U S A 2004;101:4274-4279.
27. Heinricher MM, Neubert MJ. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol 2004;92:1982-1989.
28. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-311.
29. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001;53:167-178.
30. Lew D, Burstein R, Strassman AM. Mast cell involvement in the pathophysiology of migraine headache: a hypothesis. Headache 2006;46(suppl 1):13 18.
31. Zhang XC, Strassman AM, Burstein R, et al. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J Pharmacol Exp Ther 2007:322:806-812.
32. Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002;8:136-142.
33. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mo1 Med 2007; 13: 39-44.
34. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation, J Cereb Blood Flow Metab 1999;19:115-127.
35. May A, Marharu M. New insights into migraine: application of functional and structural imaging. Curr Opin Neurol 2007;20: 306-309.
36. Fields HE, Basbaum AI. Central nervous system mechanisms of pain modulation. In: Wall PD, Melzack R, eds. Textbook of pain. 4th ed. Edinburgh: Churchill Livingstone, 1999: 309-329.
37. Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci 2002;25: 319 -325.
38. Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(lB/ 1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004;56:371-381.
39. Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience 2001;106:793-800.